Effect of the phosphodiesterase-5 inhibitor zaprinast on ischemia-reperfusion injury in rats Journal Article


Authors: Polcari, A. J.; Farooq, A. V.; Woods, M. E.; Ripsch, M. S.; Picken, M; Turk, T. M.; White, F. A.
Article Title: Effect of the phosphodiesterase-5 inhibitor zaprinast on ischemia-reperfusion injury in rats
Abstract: PURPOSE: The cardiac and renal protective effects of phosphodiesterase-5 (PDE-5) inhibitors against ischemia-reperfusion injury have recently been demonstrated in animal studies. We evaluated the effect of pretreatment with the PDE-5 inhibitor zaprinast on warm renal ischemia in a rat model. METHODS: Female Sprague-Dawley rats underwent concomitant right nephrectomy and left renal hilar occlusion for 30 minutes. Twelve animals were equally divided into three groups: Group 1 received no pharmacologic pretreatment, group 2 was pretreated with zaprinast 10 mg/kg, and group 3 was pretreated with zaprinast 20 mg/kg. Zaprinast was dissolved in 25% dimethyl sulfoxide and given as a single intraperitoneal injection 30 minutes before surgery. Serum blood urea nitrogen (BUN) and creatinine levels, histopathology, and TUNEL staining for apoptosis were assessed 24 hours postoperatively. RESULTS: The mean creatinine level for groups 1, 2, and 3 was 0.73 mg/dL, 0.55 mg/dL, and 0.38 mg/dL, respectively. These values were not statistically different (P=0.099). The mean BUN levels of 35.8 mg/dL for group 1, 27.3 mg/dL for group 2, and 23.3 mg/dL for group 3 were also statistically similar (P=0.278). There were no objective differences in histopathologic evaluation or TUNEL staining between the groups. CONCLUSION: This study did not demonstrate a beneficial effect of zaprinast pretreatment on renal parameters after warm ischemic injury.
Journal Title: Journal of endourology / Endourological Society
Volume: 27
Issue: 3
ISSN: 1557-900X; 0892-7790
Publisher: Unknown  
Journal Place: United States
Date Published: 2013
Start Page: 338
End Page: 342
Language: eng
DOI/URL:
Notes: GR: R01 NS049136/NS/NINDS NIH HHS/United States; JID: 8807503; 0 (Phosphodiesterase 5 Inhibitors); 0 (Purinones); 60-27-5 (Creatinine); GXT25D5DS0 (zaprinast); OID: NLM: PMC3608021 [Available on 03/01/14]; PMCR: 2014/03/01 00:00; ppublish